Craft

Editas Medicine

Stock Price

$3.1

2024-10-29

Market Capitalization

$256.5 M

2024-10-29

Revenue

$78.1 M

FY, 2023

Editas Medicine Summary

Company Summary

Overview
Editas Medicine is a transformative genome editing company that is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. The Company operates through developing and commercializing genome editing technology segment. Editas Medicine is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats technology.
Type
Public
Status
Active
Founded
2013
HQ
Cambridge, MA, US | view all locations
Website
http://www.editasmedicine.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Linea Aspesi

    Linea Aspesi, Executive Vice President and Chief People Officer

  • Harry Gill

    Harry Gill, Senior Vice President, Operations

  • Bruce E. Eaton

    Bruce E. Eaton, Executive Vice President, Chief Technology Officer and Chief Business Officer

  • Baisong Mei

    Baisong Mei, Senior Vice President and Chief Medical Officer

Operating MetricsView all

Patents Pending

500

FY, 2016

Patents Issued

41

FY, 2016

LocationsView all

3 locations detected

  • Cambridge, MA HQ

    United States

    11 Hurley St

  • Boulder, CO

    United States

    Westview building, 4909 Nautilus Ct N 208 211boulder

  • Cambridge, MA

    United States

    300 Third St

Editas Medicine Financials

Summary Financials

Revenue (Q3, 2024)
$61.0K
Net income (Q3, 2024)
($62.1M)
Cash (Q3, 2024)
$95.8M
EBIT (Q3, 2024)
($65.7M)
Enterprise value
$199.2M

Footer menu